Literature DB >> 17383686

MAPK pathway mediates muscarinic receptor-induced human lung fibroblast proliferation.

Sonja Matthiesen1, Amit Bahulayan, Olaf Holz, Kurt Racké.   

Abstract

Airway remodelling is a pathological feature of chronic inflammatory and obstructive airway diseases like asthma and COPD wherein fibroblasts contribute to structural alteration processes. We recently reported expression of multiple muscarinic receptors in human lung fibroblasts and demonstrated muscarinic receptor-induced, G(i)-mediated proliferation in these cells. We now explore the underlying intracellular signalling pathways. As a measure of cell proliferation ((3)H)-thymidine incorporation in primary human lung fibroblasts and MRC-5 fibroblasts was increased by about 2 fold in presence of the muscarinic receptor agonist carbachol (10 microM) and this effect could be prevented by the MEK inhibitor PD 98059 (30 microM). Western blot analysis revealed a rapid (within 2 min) activation of p42/44 MAPK (ERK1, ERK2) following exposure to 10 microM carbachol or oxotremorine, effects blocked by tiotropium as well as atropine. In conclusion, the proliferative response of lung fibroblasts to muscarine receptor stimulation is mediated via activation of the classical MEK-ERK MAPK cascade. It is suggested that prevention of cholinergic driven fibroblast proliferation by prolonged blockade of airway muscarinic receptors may contribute to the reported long term beneficial effects of anticholinergics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383686     DOI: 10.1016/j.lfs.2007.02.027

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

1.  The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts.

Authors:  F Lamyel; M Warnken-Uhlich; W K Seemann; K Mohr; E Kostenis; A S Ahmedat; M Smit; R Gosens; H Meurs; A Miller-Larsson; Kurt Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-21       Impact factor: 3.000

2.  Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system.

Authors:  A S Ahmedat; M Warnken; W K Seemann; K Mohr; E Kostenis; U R Juergens; K Racké
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Effect of penehyclidine hydrochloride on expressions of MAPK in mice with CLP-induced acute lung injury.

Authors:  Jia Zhan; Yongpan Liu; Zongze Zhang; Chang Chen; Kai Chen; Yanlin Wang
Journal:  Mol Biol Rep       Date:  2010-09-16       Impact factor: 2.316

Review 4.  Muscarinic receptor antagonists: effects on pulmonary function.

Authors:  Kalmia S Buels; Allison D Fryer
Journal:  Handb Exp Pharmacol       Date:  2012

Review 5.  Airway and lung remodelling in chronic pulmonary obstructive disease: a role for muscarinic receptor antagonists?

Authors:  Michael Roth
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

Review 6.  Pulmonary fibroblasts, an emerging target for anti-obstructive drugs.

Authors:  Kurt Racké; Susanne Haag; Amit Bahulayan; Mareille Warnken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-13       Impact factor: 3.000

Review 7.  Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans.

Authors:  I Wessler; C J Kirkpatrick
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

8.  Role of Epac1 in mediating anti-proliferative effects of prostanoid EP(2) receptors and cAMP in human lung fibroblasts.

Authors:  S Haag; M Warnken; U R Juergens; K Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-22       Impact factor: 3.000

9.  Cholinergic regulation of airway inflammation and remodelling.

Authors:  Saeed Kolahian; Reinoud Gosens
Journal:  J Allergy (Cairo)       Date:  2012-01-16

10.  Human tenocytes are stimulated to proliferate by acetylcholine through an EGFR signalling pathway.

Authors:  Gloria Fong; Ludvig J Backman; Gustav Andersson; Alexander Scott; Patrik Danielson
Journal:  Cell Tissue Res       Date:  2012-12-05       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.